Daiichi Sankyo has begun a Phase I trial to evaluate the safety and tolerability of DS-1062 in patients with unresectable advanced non-small cell lung cancer (NSCLC).

The open-label trial will examine DS-1062 in NSCLC patients that are resistant to standard treatment or have relapsed.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The first part of the trial will study the safety and tolerability of increasing doses of DS-1062 to identify the maximum tolerated dose and recommended dose for expansion. The second part of the study will assess the safety and tolerability of DS-1062 at the recommended dose for expansion.

“With the initiation of this study of DS-1062, we move our third antibody-drug conjugate (ADC) into the clinic and continue to investigate the potential of the smart delivery of chemotherapy in various cancers.”

The trial’s endpoints are safety, pharmacokinetics, objective response rate, duration of response, disease control rate, time to response, progression-free survival, overall survival, biomarker analysis and immunogenicity.

The study aims to enrol roughly 40 patients with unresectable advanced NSCLC in the US and Japan.

Daiichi Sankyo oncology research and development executive vice-president and global head Antoine Yver said: “We are initially focusing on evaluating DS-1062 in patients with advanced NSCLC with potential expansion into other tumour types depending on the results of this early critical test in a study designed to provide evidence supporting unique properties of this particular TROP2 ADC construct.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“With the initiation of this study of DS-1062, we move our third antibody-drug conjugate (ADC) into the clinic and continue to investigate the potential of the smart delivery of chemotherapy in various cancers, including lung, breast and gastric cancer.”

Daiichi Sankyo’s DS-1062 is an investigational trophoblast cell-surface antigen 2-(TROP2)-targeting ADC.

It is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now